Patients with primary brain tumors such as malignant gliomas are highly symptomatic, often
from the time of diagnosis. Signs and symptoms (signs/symptoms) can cause functional …

Glioblastoma (GBM) represents the most frequent primary brain tumor in adults and carries a
dismal prognosis despite aggressive, multimodal treatment regimens involving maximal …

Primary brain tumor patients often experience neurological, cognitive, and depressive
symptoms that profoundly affect quality of life. The DNA alkylating agent, temozolomide …

Glioblastoma, the most common primary brain tumor in adults, has one of the most dismal
prognoses in cancer. In 2009, bevacizumab was approved for recurrent glioblastoma in the …

Compared to traditional chemotherapies, where dose limiting toxicities represent the
maximum possible dose, monoclonal antibody therapies are used at doses well below …

Background For recurrent high-grade glioma, especially glioblastoma, no standard of care
treatment exists. Due to the prolongation of progression-free survival and a cortiocosteroid …

Purpose The AVAglio trial established the beneficial effect of add-on bevacizumab (BEV) for
the treatment of newly diagnosed glioblastomas (nd-GBMs) that led to the approval of BEV …

Aim: Intrapleural infusion of bevacizumab (BEV) is an emerging clinical treatment for
malignant pleural effusion, but many details of usage need to be determined, especially for …

Malignant gliomas (MG) are very aggressive tumors. In an effort to improve the outcome, the
patients receive multi-modal therapies such as surgery, radiation and chemotherapy …

脑胶质瘤是成人最常见的原发性脑肿瘤, 也是肿瘤中预后最差的肿瘤之一.
目前的常规治疗方法以手术切除为主, 术后放疗联合替莫唑胺(temozolomide, TMZ) …